



Please type a plus sign (+) inside this box



PTO/SB/83 (08-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REQUEST FOR WITHDRAWAL AS ATTORNEY OR AGENT

Application Number	09/155,739
Filing Date	09/11/98
First Named Inventor	Mary M. Bendig et al.
Group Art Unit	1644
Examiner Name	Phillip Gambel
Attorney Docket Number	015270-001430US

To: Assistant Commissioner for Patents  
Washington, DC 20231

I hereby apply to withdraw as attorney or agent for the attached identified applications

The reasons for this request are: request of assignee  
see Exhibit A

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

- ☐ The correspondence address is NOT affected by this withdrawal.
- ☒ Change the correspondence address and direct all future correspondence to:

### CORRESPONDENCE ADDRESS

☐ Customer Number  
OR

Place Customer Number  
Bar Code Label here

☒ Firm or  
Individual Name

Teresa Stanek Rea, Esq.

Address

Burns Doane Swecker & Mathis, LLP

Address

1737 King Street, Suite 500

City

Alexandria

State

VA

ZIP

22314

Country

U.S.A.

Telephone

703-836-6620

Fax

703-836-2021

This request is enclosed in triplicate.

Name

Joe Liebeschuetz, Reg. No. 37,505

Signature

*J. Liebeschuetz*

Date

6/11/2002

NOTE: Withdrawal is effective when approved rather than when received  
Unless there are at least 30 days between approval of withdrawal and the expiration date of a time  
period for response or possible extension period, the request to withdraw is normally disapproved.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3228586 v1

APPROVED

*William M. White*  
5/17/02, TC/600  
6/27/02

3/06/94 14:40 FAX  
OFFICE  
JUN 17 2002  
PATENT & TRADEMARK OFFICE  
**élan**

**COPY**

800 Gateway Boulevard  
South San Francisco, CA 94080  
T (650) 877 0900  
F (650) 877 8370  
Direct Legal T: (650) 794-4375  
Direct Legal F: (650) 553 7165

**FAX**

To Andrew Serafini, Esq.  
Townsend Townsend & Crew

Fax 650-326-2422

From Joe Liebeschuetz, Esq.  
Townsend Townsend & Crew  
Dianna DeVore  
Associate Director, Patents  
Elan Pharmaceuticals Inc.

Date May 8, 2002

Copy

Page Page 1 of 5

Subject **Transfer of Prosecution Responsibility**

Please see attached.

**RECEIVED**

JUN 21 2002

TECH CENTER 1600/2900

*If transmission was faulty, contact: FAYE KNOWLES @ (650) 866-2774*

Elan Pharmaceuticals, Inc.  
a member of the Elan Group

Warning: This communication is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return this original message to us at the above address via the mail service. Thank you.



800 Gateway Boulevard  
South San Francisco, CA 94080  
T (650) 877 0900 F (650) 877 8370

May 8, 2002

Andrew Serafini, Esq.  
Townsend & Townsend & Crew  
379 Lytton Avenue  
Palo Alto, CA 94301-1431

**Sent Via Facsimile to: 650-326-2422**  
**Original sent via U.S. Mail**

Re: Transfer of Prosecution Responsibility

For: BLOOD BRAIN BARRIER MODEL  
Our Reference No.: 101 Series  
Your Reference No.: 15270-0032 Series

For: HUMANIZED ANTIBODIES AGAINST LEUKOCYTE  
ADHESION MOLECULE VLA-4  
Our Reference No.: 120 Series  
Your References No. 15270-0014

For: TREATMENT OF VIRAL ENCEPHALITIS BY AGENTS  
BLOCKING ALPHA-4 INTEGRIN FUNCTION  
Our Reference No.: 00188 US Case  
Your Reference No.: 015270-004300US

Dear Andrew:

We have decided to transfer in their entirety all cases as listed on attached Exhibit A to Burns, Doane Swecker & Mathis, LLP. Accordingly, please transfer the original files to the following address:

Teresa Stanek Rea, Esq..  
Burns Doane Swecker & Mathis, LLP  
Suite 500  
1737 King Street  
Alexandria, VA 22314-2727

Please include a list of all outstanding items, and both an action and regular docket for all cases listed in Exhibit A.

BIOPHARMACEUTICALS

Elan Pharmaceuticals, Inc.  
a member of the Elan Group

05/08/02  
Andrew Serafini, Esq.  
May 8, 2002  
Page 2

We have been pleased with your firm and hope to continue our relationship for the remaining Elan cases currently handled by Townsend.

Please acknowledge receipt of these files by kindly returning one copy of this letter to us at your earliest convenience.

Should you have any questions, feel free to contact me at (650) 794-4375.

Very truly yours,



Dianna DeVore  
Associate Director, Patents

Enclosures

DLD/fdk

cc: Joe Liebeschutz, Esq. (w/ enclosures)  
Teresa Stanek Rea, Esq. (w/ enclosures)  
Jean Duvall, Esq. (w/o enclosures)

**RECEIPT IS ACKNOWLEDGED OF THE ABOVE-IDENTIFIED FILES:**

Date: \_\_\_\_\_

By: \_\_\_\_\_

03/06/96 14:30 FAX 0000000000  
Andrew Serafini, Esq.  
May 8, 2002  
Page 3

**EXHIBIT A**

**Elan Reference No.**

**Patent/Serial No.**

**Townsend Reference No.**

**Your Reference No.**

**15270-0032**

**Including:**

101-US-CIP1  
101-CA-CIP1  
101-JP-CIP1  
101-US-CON2  
101-US-CON3

5,260,210  
2,066,73 8  
2-513049  
08/402,962  
6,033,665

15270-003210US  
15270-003210CA  
15270-003210JP ✓  
15270-003213US  
15270-003215US

**Elan Reference No.**

**Patent/Serial No.**

**Townsend Reference No.**

**Your Reference No.**

**15270-0014**

**Including:**

120-AU-NEW  
120-CA-NEW  
120-CA-CIP1  
120-CN-NEW  
120-EPO-CIP1  
120-EPO-NEW  
120-FI-NEW  
120-HU-NEW  
120-JP-CIP1  
120-JP-NEW  
120-KR-NEW  
120-MX-NEW  
120-NO-NEW  
120-NZ-NEW  
120-PL-NEW  
120-US-CIP1

703152  
2,182,013  
2,237,808  
95191354.9  
96943512.2  
95908741.2  
962958  
P9602019  
9-519938  
7-519770  
96-703987  
198845  
96.3097  
279730  
P315634  
09/155,739

15270-001410AU  
15270-001410CA  
15270-001430CA  
15270-001410CN  
15270-001430EP  
15270-001410EP  
15270-001410FI  
15270-001410HU  
15270-001430JP  
15270-001410JP  
15270-001410KR  
15270-001410MX  
15270-001410NO  
15270-001410NZ  
15270-001410PL  
15270-001430US

Andrew Serafini, Esq.  
May 8, 2002  
Page 4

**Elan Reference No.**

**Patent/Serial No.**

**Townsend Reference No.**

**Your Reference No.**  
**15270-0014**  
**Including:**

120-US-CIP2  
120-PCT-NEW  
120-PCT-CIP1

5,840,299  
PCT/US95/01219  
PCT/US96/18807

15270-001420US  
15270-14-1PC  
15270-1430PC

**Elan Reference No.**

**Patent/Serial No.**

**Townsend Reference No.**

**Your Reference No.**  
**15270-0043**  
**Including:**

188-US-NEW

09/010,377

15270-004300US